Is enactuzumab already included in the medical insurance catalog?

As of now (2025.6), Elranatamab has not been included in China’s National Medical Insurance Drug List. Although the drug has received marketing approval from the China National Medical Products Administration for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) and is one of the first BCMA/CD3 bispecific antibodies to enter China, due to its short time on the market, it has not yet entered the medical insurance negotiation process or failed to pass the medical insurance bureau negotiation mechanism.

Inclusion in the medical insurance catalog usually requires comprehensive consideration of multi-dimensional factors such as the clinical effectiveness and safety of the drug, the urgent needs of the treatment population, the cost-effectiveness ratio of the drug, foreign pricing conditions, and domestic usage predictions. Although enantuzumab has shown clear efficacy in the treatment of patients with highly drug-resistant multiple myeloma, and is especially suitable for patients who have failed previous treatments with proteasome inhibitors, immunomodulators, and anti-CD38 antibodies, there is currently a lack of large-scale real-world data in China to support its value for medical insurance inclusion.

In addition, the drug is currently an imported original biological drug with a relatively high price, which also poses a certain threshold in the economic evaluation of medical insurance. To be included in medical insurance, pharmaceutical companies usually need to negotiate with the medical insurance bureau and provide room for price concessions in exchange for wider patient use opportunities. In the past, similar biological drugs such as daratumumab and ixazomib also went through several rounds of negotiations before entering the medical insurance catalog, and finally achieved a significant price drop before being included. If Enantuzumab wants to copy this path, it will need to wait for the next round of medical insurance catalog updates or special negotiations.

However, it is worth noting that without being included in the medical insurance catalog at this stage, there may be temporary procurement mechanisms and charity assistance projects within hospitals or medical consortiums in some areas. Patients can learn more about alternative payment channels based on the place of treatment and the doctor’s recommendations.

Reference materials:https://www.drugs.com/mtm/elranatamab.html